Group 1 - Wuxi City held an innovation achievement exchange meeting focusing on "integration of production, medicine, and research" in healthcare, announcing 9 innovative results aimed at benefiting the public [1] - A new round of cooperation agreement was signed between Wuxi and the National Cancer Center to enhance cancer prevention actions, exploring seamless connections in early screening, diagnosis, and treatment to reduce medical costs and family financial burdens [1] - The "Yihui Xicheng" new product and "One-click e-compensation" feature will be launched in 2026, introducing innovative drug and device coverage and increasing DRG exclusions to further alleviate the medical burden on citizens [1] Group 2 - Wuxi announced the introduction of a new batch of medical expert teams and high-level healthcare talents, establishing a clinical trial institution alliance and releasing the first batch of biopharmaceutical innovation product catalog for 2025 [2] - The Wuxi Guolian Health Foundation was officially established with an initial fundraising of 30 million yuan for medical research, talent training, and support for disadvantaged groups [2] - Eight banks jointly launched a special loan product for biomedicine, providing a total credit limit of 16 billion yuan to the first batch of 16 enterprises [2] Group 3 - Wuxi has accelerated the high-quality development of "integration of production, medicine, and research" in healthcare, achieving a total of 3 first-class innovative drugs and 8 second and third-class innovative medical devices listed [2] - Over the past three years, Wuxi has supported 31 projects combining medicine and engineering, and has been recognized as one of the top 20 cities in China's biopharmaceutical industry development index for two consecutive years [2] - The biopharmaceutical cluster in Wuxi has been selected as a national advanced manufacturing cluster [2]